COVID-19疫苗接种对脾切除后免疫性血小板减少症患者的保护作用
本研究为纵向研究,纳入191例脾切除后免疫性血小板减少症(ITP)患者,中位随访114个月后146例(76.4%)对脾切除持续应答。COVID-19感染期间,接种疫苗患者的重症感染(OR 0.13)、住院(OR 0.13)和ITP加重(OR 0.16)风险均更低。
要点
- 脾切除后ITP患者中位随访114个月,76.4%持续应答。
- 接种COVID-19疫苗者重症感染风险更低(OR 0.13)。
- 接种疫苗者住院和ITP加重风险亦更低(OR 0.13和0.16)。
核心结论
- COVID-19疫苗接种对脾切除后ITP患者具有保护作用。
研究设计与样本
- 纵向研究,纳入191例脾切除后免疫性血小板减少症患者。
主要发现
- 中位随访114个月后,146例(76.4%)患者对脾切除持续应答。
- COVID-19感染期间,接种疫苗患者重症感染风险更低(OR 0.13,95%CI 0.05-0.36,p<0.001)。
- 接种疫苗患者住院风险更低(OR 0.13,95%CI 0.04-0.48,p=0.002)。
- 接种疫苗患者ITP加重风险更低(OR 0.16,95%CI 0.04-0.67,p=0.012)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Splenectomy is an effective treatment for immune thrombocytopenia (ITP). The effect of COVID-19 vaccination on splenectomized patients with ITP during the COVID-19 pandemic has not been reported. Therefore, this study aimed to investigate the effect of COVID-19 vaccination on clinical outcomes in these patients. This was a longitudinal study of splenectomized patients with ITP. A total of 191 splenectomized patients were included in this study. After a median follow-up of 114 months, 146 (76.4%) patients had a sustained response to splenectomy. During COVID-19 infection, vaccinated patients showed a lower risk of severe infections (odds ratio [OR], 0.13; 95% confidence interval [CI]: 0.05-0.36; p < 0.001), hospitalization (OR, 0.13; 95% CI, 0.04-0.48; p = 0.002), and ITP exacerbation (OR, 0.16; 95% CI, 0.04-0.67; p = 0.012). These findings indicate that COVID-19 vaccination plays a protective role in splenectomized patients with ITP.
引用
- Liu X, Gan X, Xu J, et al. Protective effects of COVID-19 vaccination in splenectomized patients with immune thrombocytopenia. Br J Haematol. 2024. PMID: 38632670. doi:10.1111/bjh.19405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。